Independent Laboratory Testing Shows BioNeutral's Hospital Grade Ygiene(TM) Eliminates...

Independent Laboratory Testing Shows BioNeutral's Hospital Grade Ygiene(TM)
Eliminates Aspergillus Niger (Black Mold) Spores

NEWARK, N.J., July 7 /PRNewswire-FirstCall/ -- BioNeutral Group, Inc.
("BioNeutral") (OTC Bulletin Board: BONU), a chemical technology-based Life
Science company announced today that independent laboratory testing performed
by ATS Labs shows that Aspergillus Niger mold spores are completely eliminated
by the Company's Ygiene(TM) Hospital Grade antimicrobial in record time.

ATS Labs, using the EPA required Fungicidal Use Dilution test, showed that
approximately 2.5 million Aspergillus Niger spores were totally eliminated
within two (2) minutes. Aspergillus Niger is a type of black mold spore which
is a prolific human heath threatening problem. The spore form of this black
mold is particularly difficult to eliminate and total eradication is required
in order to alleviate associated health threatening issues.

BioNeutral's Chief Science Officer, Dr. Andy Kielbania, PhD. stated, "These
results are particularly important because they both validate our internal lab
testing protocols and also confirm the speed, efficacy and power of our
Ygiene(TM) antimicrobials. The sporicidal efficacy against Aspergillus Niger
(Black Mold) is a key accomplishment for our company." He continued, "These
independent lab test results represent a significant achievement. Based upon
these results we believe our hospital grade Ygiene(TM) will easily eliminate
any health threatening bacteria including very dangerous and difficult to kill
antibiotic resistant forms including, Methicillan Resistant Staphylococcus
Aureus often referred to as "MRSA", drug resistant Pseudomonas Aeruginosa and
the very difficult to eradicate pan resistant Klebsiella Pneumoniae.
Obviously the new strain of H1N1 virus (Swine Flu) will not present any
problem for our formula to achieve a total Kill in record time."

In an article in Environmental Business International, Inc., The Chelsea
Group, an Indoor Air Quality (IAQ) consulting and market research firm,
estimates the IAQ market caused by toxic mold to be $2 to $3 billion annually
and Anthony Worthan, President and COO of Air Quality Sciences, an IAQ
consulting firm in Atlanta, estimates the IAQ market to be growing at an
annual rate of 25%.

"These positive independent laboratory results validate that our Hospital
Grade formula is now well on its way to becoming the next generation
technology in EPA approved disinfectants and sterilants for health care
facilities around the world," stated Stephen J. Browand, President and CEO of
BioNeutral Group, Inc. "I am confident that our rigorous independent testing
program will continue to validate our advanced technology performance with a
100% Total Kill at record speed, while also remaining friendly to people and
the environment."

About ATS Labs:

ATS Labs, http://www.ats-labs.com is a leading internationally recognized lab
used by the developers and users of antimicrobial products. They provide
comprehensive antimicrobial service and their superior client service and
scientific data have earned them a distinguished record of acceptance with
regulatory agencies in the U.S., Canada and the world.

About BioNeutral Group, Inc.

Headquartered at the New Jersey Institute of Technology/EDC in Newark, New
Jersey, BioNeutral Group, Inc., is a chemical technology-based Life Science
company that intends to commercialize a combinational chemistry-based
technology which can neutralize harmful environmental contaminants, toxins and
dangerous micro-organisms including bacteria, viruses, mold, fungi and spores.
The formulations, including Ygiene(TM) and Ogiene(TM), which are eco-friendly
and include natural and common ingredients which are found in baby products
and in every day foods. The Company has combined these widely-used compounds
in highly specialized ways to create products that dramatically enhance
disinfecting and cleaning results; products include BioNeutralizers and
ChemoNeutralizers. BioNeutral's proprietary platform technology has been
proven effective in surface, water and airborne applications.

More information about the Company may be found at www.bioneutralgroup.com

Forward-Looking Statements

BioNeutral routinely tests its formulations against those of its competitors.
The results are published to let shareholders know how the Company's
technology compares with known formulations in the market place. Any product
claim for antimicrobial activity requires approval from the EPA or FDA,
depending upon where and how the formulations are used. The EPA and FDA have
not reviewed or confirmed the Company's data and findings. BioNeutral's
antimicrobial formulations will be marketed under the brand name Ygiene(TM)
and are not yet available for sale in the United States.

Contact Information
BioNeutral Group Inc.
Stephen J. Browand, President and CEO
steve@bioneutralgroup.com

Investor Relations
Aimee Boutcher
973 239-2878
aboutcher@aol.com

SOURCE BioNeutral Group, Inc.

Stephen J. Browand, President and CEO, BioNeutral Group Inc.,
steve@bioneutralgroup.com; or Aimee Boutcher, Investor Relations,
+1-973-239-2878, aboutcher@aol.com